Trials / Completed
CompletedNCT04479644
Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198
A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibody, BRII-198 Administered Intravenously to Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Brii Biosciences Limited · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 1 study in which healthy adult volunteers will receive BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BRII-198 | BRII-198 given intravenously |
| DRUG | Placebo | Placebo given intravenously |
Timeline
- Start date
- 2020-07-13
- Primary completion
- 2021-02-03
- Completion
- 2021-02-03
- First posted
- 2020-07-21
- Last updated
- 2023-03-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04479644. Inclusion in this directory is not an endorsement.